Your browser doesn't support javascript.
loading
Successful treatment of severe cytokine release syndrome after CAR-T therapy by ruxolitinib without compromising CAR-T efficacy.
Gu, Chengyuan; Wu, Qian; Zhang, Jingren; Kang, Liqing; Yu, Lei; Qiu, Huiying; Wu, Depei; Chen, Suning; Yang, Xiaofei.
Afiliação
  • Gu C; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Wu Q; Institute of Blood and Marrow Transplantation, Suzhou, China.
  • Zhang J; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
  • Kang L; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Yu L; Institute of Blood and Marrow Transplantation, Suzhou, China.
  • Qiu H; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
  • Wu D; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Chen S; Institute of Blood and Marrow Transplantation, Suzhou, China.
  • Yang X; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
Leuk Lymphoma ; 64(2): 495-498, 2023 02.
Article em En | MEDLINE | ID: mdl-36395278
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores de Antígenos Quiméricos Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores de Antígenos Quiméricos Idioma: En Ano de publicação: 2023 Tipo de documento: Article